Ser301
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.5
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser301  -  EGR1 (human)

Site Information
AFATQSGsQDLKALN   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 11423702

In vivo Characterization
Methods used to characterize site in vivo:
electrophoretic mobility shift ( 2 ) , mass spectrometry ( 1 ) , mass spectrometry (in vitro) ( 1 ) , mutation of modification site ( 1 )
Disease tissue studied:
leukemia ( 1 ) , T cell leukemia ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
DNAPK (human) ( 1 )
Kinases, in vitro:
CK2A1 (rat) ( 2 ) , DNAPK (human) ( 1 )
Treatments:
NU7441 ( 1 ) , phorbol_ester ( 1 ) , phytohemagglutinin ( 1 )

Downstream Regulation
Effects of modification on EGR1:
protein stabilization ( 1 )
Effects of modification on biological processes:
transcription, altered ( 2 ) , transcription, induced ( 1 )
Inhibit interaction with:
DNA ( 2 )

References 

1

Waldrip ZJ, et al. (2021) DNA-PKcs kinase activity stabilizes the transcription factor Egr1 in activated immune cells. J Biol Chem, 101209
34562454   Curated Info

2

Jain N, et al. (1996) Casein kinase II associates with Egr-1 and acts as a negative modulator of its DNA binding and transcription activities in NIH 3T3 cells. J Biol Chem 271, 13530-6
8662759   Curated Info